Compare AbCellera Biologics Inc (ABCL) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs MGM Resorts International — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while MGM Resorts International trades at $46.38 (market cap $11.93B). The key difference: MGM Resorts International is far larger — about 5.1× AbCellera Biologics Inc's market cap, and MGM Resorts International pays a 0.03% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MGM | |
|---|---|---|
Market Cap | $2.35B | $11.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $50.69 |
52-Week Low | $2.78 | $30.72 |
Enterprise Value | $1.99B | $40.98B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MGM Resorts International (MGM) trades at $46.64, down 0.98% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.49, slightly missing expectations, while Q4 2025 saw a significant beat. Revenue growth has been steady, reaching $17.54B in 2025, though net income margins have compressed to 1.03%. Recent news highlights a potential acquisition offer from Barry Diller at $48.30 per share, under investigation by BFA Law.
The outlook for MGM is cautiously optimistic, supported by analyst consensus leaning Buy (48.64%) and a price target of $45.45. Opportunities include strategic partnerships and digital expansion via BetMGM, but risks persist from high debt levels, regulatory scrutiny, and volatile earnings performance. Investors should weigh the acquisition premium against fundamental valuation metrics like a high P/E of 64.22.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
